Azacitidine: A Review of its Use in Higher-Risk Myelodysplastic Syndromes/Acute Myeloid Leukaemia

By Keating Gillian M.  

Drugs, Vol. 69, Iss. 17, 2009-12 ,pp. : 2501-2518

Adis International

Access to resources Recommend Favorite

Orbofiban: higher risk of thrombocytopenia

By  

Reactions Weekly, Vol. 1, Iss. 1129, 2006-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Antihistamine benefits substantial but costs of sedation even higher

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 462, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Antihistamine benefits substantial but costs of sedation even higher

By  

Inpharma, Vol. 1, Iss. 1456, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium

By Jabbour Elias J.   Garcia-Manero Guillermo   Strati Paolo   Mishra Asmita   Al Ali Najla H.   Padron Eric   Lancet Jeffrey   Kadia Tapan   Daver Naval   O'Brien Susan   Steensma David P.   Sekeres Mikkael A.   Gore Steven D.   Dezern Amy   Roboz Gail J.   List Alan F.   Kantarjian Hagop M.   Komrokji Rami S.  

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 876-882

Blackwell Publishing

Access to resources Recommend Favorite